The urothelium covers the luminal surface of almost the entire urinary tract, extending from the renal pelvis, through the ureter and bladder, to the proximal urethra. The majority of urothelial carcinomas are bladder carcinomas, and urothelial carcinomas of the renal pelvis and ureter account for only approximately 7% of the total. Urothelial tumors arise and evolve through divergent phenotypic pathways. Some tumors progress from urothelial hyperplasia to low-grade non-invasive superficial papillary tumors. More aggressive variants arise either from flat, high-grade carcinoma in situ (CIS) and progress to invasive tumors, or they arise de novo as invasive tumors. Low-grade papillary tumors frequently show a constitutive activation of the receptor tyrosine kinase-Ras pathway, exhibiting activating mutations in the HRAS and fibroblast growth factor receptor 3 (FGFR3) genes. In contrast, CIS and invasive tumors frequently show alterations in the TP53 and RB genes and pathways. Invasion and metastases are promoted by several factors that alter the tumor microenvironment, including the aberrant expression of E-cadherins (E-cad), matrix metalloproteinases (MMPs), angiogenic factors such as vascular endothelial growth factor (VEGF). Phosphorylation sites were added based on information from PhosphoSitePlus (R), https://www.phosphosite.org.
Proteins on this pathway have targeted assays available via the [https://assays.cancer.gov/available_assays?wp_id=WP2828 CPTAC Assay Portal]
c0b
b1b
d0d
d79
fca
parentid=P06400; parentsymbol=RB1; site=strPPtLsPIPHIPr; position=ser780; sitegrpid=447978; ptm=p; direction=d
parentid=O75582; parentsymbol=RPS6KA5; site=PDNQPLKtPCFTLHY; position=thr581; sitegrpid=448217; ptm=p; direction=u
parentid=Q02750; parentsymbol=MAP2K1; site=VsGQLIDsMANsFVG; position=ser218; sitegrpid=448514; ptm=p; direction=u
parentid=Q02750; parentsymbol=MAP2K1; site=LIDsMANsFVGTRSY; position=ser222; sitegrpid=448513; ptm=p; direction=u
parentid=P36507; parentsymbol=MAP2K2; site=LIDsMANsFVGTRSY; position=ser226; sitegrpid=448074; ptm=p; direction=u
parentid=P36507; parentsymbol=MAP2K2; site=VsGQLIDsMANsFVG; position=ser222; sitegrpid=448073; ptm=p; direction=u
parentid=P28482; parentsymbol=MAPK1; site=HtGFLtEyVAtRWyR; position=tyr187; sitegrpid=447594; ptm=p; direction=u
parentid=P28482; parentsymbol=MAPK1; site=HDHtGFLtEyVAtRW; position=thr185; sitegrpid=447593; ptm=p; direction=u
a4f
a4f
a4f
fd5
a4f
a4f
a4f
a4f
a4f
a4f
a4f
a4f
a4f
a4f
a4f
a4f
a4f
25514926
PubMed
PhosphoSitePlus, 2014: mutations, PTMs and recalibrations.
Nucleic Acids Res
2015
Hornbeck PV
Zhang B
Murray B
Kornhauser JM
Latham V
Skrzypek E
bladder disease
DOID:365
Disease
urinary bladder cancer
DOID:11054
Disease
bladder urothelial cell
CL:1001428
Cell Type
cancer pathway
PW:0000605
Pathway Ontology
cancer
DOID:162
Disease
22417847
PubMed
Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Hum Pathol
2012
Juanpere N
Agell L
Lorenzo M
de Muga S
Lأ³pez-Vilarأ³ L
Murillo R
Mojal S
Serrano S
Lorente JA
Lloreta J
Hernأ،ndez S
23175443
PubMed
Oncogenic FGFR3 gene fusions in bladder cancer.
Hum Mol Genet
2013
Williams SV
Hurst CD
Knowles MA
map05219
KEGG Pathway
Bladder Cancer Pathway
http://www.genome.jp/dbget-bin/www_bget?pathway:map05219
disease pathway
PW:0000013
Pathway Ontology
24122582
PubMed
PI3K/AKT pathway activation in bladder carcinogenesis.
Int J Cancer
2014
Calderaro J
Rebouissou S
de Koning L
Masmoudi A
Hأ©rault A
Dubois T
Maille P
Soyeux P
Sibony M
de la Taille A
Vordos D
Lebret T
Radvanyi F
Allory Y
papillary renal cell carcinoma
DOID:4465
Disease
22899908
PubMed
A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges.
Adv Urol
2012
di Martino E
Tomlinson DC
Knowles MA
16474624
PubMed
Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer.
http://www.ncbi.nlm.nih.gov/pubmed/16474624
2005
Wolf EM
Liang G
Jones PA